Xilio Therapeutics (XLO) Other Non Operating Income (2020 - 2026)
Xilio Therapeutics (XLO) posted Other Non Operating Income of $1.3 million for Q1 2026, up 39.31% sequentially from $921000.0 in Q4 2025, and up 118.94% YoY from $586000.0 in Q1 2025.
Xilio Therapeutics (XLO) Other Non Operating Income (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Other Non Operating Income for 7 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Other Non Operating Income rose 118.94% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 31.97% YoY) and the FY2025 annual result came in at $1.1 million, down 52.97% from the prior year.
- Other Non Operating Income advanced to $1.3 million in Q1 2026 per XLO's latest filing, from $921000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1.3 million in Q1 2026 and troughed at -$1.4 million in Q2 2025.
- A 5-year average of $493000.0 and a median of $613000.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income soared 1347.54% in 2023, then plunged 283.31% in 2025.
- Over 5 years, Other Non Operating Income stood at $701000.0 in 2022, then slumped by 32.24% to $475000.0 in 2023, then increased by 12.84% to $536000.0 in 2024, then soared by 71.83% to $921000.0 in 2025, then soared by 39.31% to $1.3 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $1.3 million, $921000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 536,000.00 |
| Sep 30, 2024 | 742,000.00 |
| Jun 30, 2024 | 779,000.00 |
| Mar 31, 2024 | 284,000.00 |
| Dec 31, 2023 | 475,000.00 |
| Sep 30, 2023 | 613,000.00 |
| Jun 30, 2023 | 761,000.00 |
| Mar 31, 2023 | 880,000.00 |
| Dec 31, 2022 | 701,000.00 |
| Sep 30, 2022 | 416,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | -129,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | -290,000.00 |